Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Retinitis Pigmentosa
- Main trialPhase 1/2
- “This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).”In the company’s words, NCT05748873 on ClinicalTrials.gov
Other drugs for Retinitis Pigmentosa
- RTx-015Ray Therapeutics, Inc. · Phase 2/3
- N-acetylcysteine amideNacuity Pharmaceuticals, Inc. · Phase 3
- Voretigene neparvovec-rzylSpark Therapeutics, Inc. · Phase 3
- BS01Bionic Sight LLC · Phase 1/2
- FamzeretceljCyte, Inc · Phase 2
- OCU400Ocugen · Phase 1/2
Coming up1
- Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Feb 2027 | Promising ROd-cone DYstrophy Gene therapY |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026